<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02534506</url>
  </required_header>
  <id_info>
    <org_study_id>CA186-110</org_study_id>
    <nct_id>NCT02534506</nct_id>
  </id_info>
  <brief_title>Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors</brief_title>
  <official_title>A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Immunoregulatory Activity of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Malignant Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ono Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and tolerability of BMS-663513 in subjects
      with advanced and/or metastatic malignant tumors.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 6, 2015</start_date>
  <completion_date type="Actual">November 11, 2016</completion_date>
  <primary_completion_date type="Actual">November 11, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of urelumab monotherapy as measured by the dose limiting toxicity (DLT) in subjects with advanced and/or metastatic malignant tumors</measure>
    <time_frame>From day 1 of treatment up to 60 days of follow-up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of urelumab monotherapy as measured by adverse events (AEs) and serious adverse events (SAEs) in subjects with advanced and/or metastatic malignant tumors</measure>
    <time_frame>From day 1 of treatment up to 60 days of follow-up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability of urelumab monotherapy as measured by the DLT in subjects with advanced and/or metastatic malignant tumors</measure>
    <time_frame>From day 1 of treatment up to 60 days of follow-up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability of urelumab monotherapy as measured by AEs and SAEs in subjects with advanced and/or metastatic malignant tumors</measure>
    <time_frame>From day 1 of treatment up to 60 days of follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of urelumab-nivolumab combination therapy as measured by AEs and SAEs in subjects with advanced and/or metastatic malignant tumors</measure>
    <time_frame>From day 1 of treatment up to 100 days of follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability of urelumab-nivolumab combination therapy as measured by AEs and SAEs in subjects with advanced and/or metastatic malignant tumors</measure>
    <time_frame>From day 1 of treatment up to 100 days of follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (Maximum observed serum concentration) of urelumab when administered alone</measure>
    <time_frame>Cycle 1, 2, 3, 4, 5, 6, 7, 12, 16, up to 60 days of follow up</time_frame>
    <description>21 days/cycle for Urelumab monotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough (Trough observed serum concentration) of urelumab when administered alone</measure>
    <time_frame>Cycle 1, 2, 3, 4, 5, 6, 7, 12, 16, up to 60 days of follow up</time_frame>
    <description>21 days/cycle for Urelumab monotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax (Time of maximum observed serum concentration) of urelumab when administered alone</measure>
    <time_frame>Cycle 1, 2, 3, 4, 5, 6, 7, 12, 16, up to 60 days of follow up</time_frame>
    <description>21 days/cycle for Urelumab monotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-T) [Area under the concentration-time curve from time zero to the last quantifiable concentration] of urelumab when administered alone</measure>
    <time_frame>Cycle 1, 2, 3, 4, 5, 6, 7, 12, 16, up to 60 days of follow up</time_frame>
    <description>21 days/cycle for Urelumab monotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(TAU) [Area under the concentration-time curve in one dosing interval] of urelumab when administered alone</measure>
    <time_frame>Cycle 1, 2, 3, 4, 5, 6, 7, 12, 16, up to 60 days of follow up</time_frame>
    <description>21 days/cycle for Urelumab monotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(INF) [Area under the concentration-time curve from time zero to infinity and the extrapolated area] of urelumab when administered alone</measure>
    <time_frame>Cycle 1, 2, 3, 4, 5, 6, 7, 12, 16, up to 60 days of follow up</time_frame>
    <description>21 days/cycle for Urelumab monotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T-HALF (Elimination half life) of urelumab when administered alone</measure>
    <time_frame>Cycle 1, 2, 3, 4, 5, 6, 7, 12, 16, up to 60 days of follow up</time_frame>
    <description>21 days/cycle for Urelumab monotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLT (Total body clearance) of urelumab when administered alone</measure>
    <time_frame>Cycle 1, 2, 3, 4, 5, 6, 7, 12, 16, up to 60 days of follow up</time_frame>
    <description>21 days/cycle for Urelumab monotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vss (Volume of distribution at steady state) of urelumab when administered alone</measure>
    <time_frame>Cycle 1, 2, 3, 4, 5, 6, 7, 12, 16, up to 60 days of follow up</time_frame>
    <description>21 days/cycle for Urelumab monotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AI (Accumulation Index: ratio of AUC(TAU) and Cmax in cycle at steady state to those after the first cycle) of urelumab when administered alone</measure>
    <time_frame>Cycle 1, 2, 3, 4, 5, 6, 7, 12, 16, up to 60 days of follow up</time_frame>
    <description>21 days/cycle for Urelumab monotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of urelumab when co-administered</measure>
    <time_frame>Cycle 1, 2, 3, 4, 5, 6, 9, up to 100 days of follow up</time_frame>
    <description>28 days/cycle for combination therapy of Urelumab and Nivolumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coeff of urelumab when co-administered</measure>
    <time_frame>Cycle 1, 2, 3, 4, 5, 6, 9, up to 100 days of follow up</time_frame>
    <description>28 days/cycle for combination therapy of Urelumab and Nivolumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough of urelumab and nivolumab when co-administered</measure>
    <time_frame>Cycle 1, 2, 3, 4, 5, 6, 9, up to 100 days of follow up</time_frame>
    <description>28 days/cycle for combination therapy of Urelumab and Nivolumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of urelumab and nivolumab when co-administered</measure>
    <time_frame>Cycle 1, 2, 3, 4, 5, 6, 9, up to 100 days of follow up</time_frame>
    <description>28 days/cycle for combination therapy of Urelumab and Nivolumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-T) of urelumab and nivolumab when co-administered</measure>
    <time_frame>Cycle 1, 2, 3, 4, 5, 6, 9, up to 100 days of follow up</time_frame>
    <description>28 days/cycle for combination therapy of Urelumab and Nivolumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(TAU) of urelumab and nivolumab when co-administered</measure>
    <time_frame>Cycle 1, 2, 3, 4, 5, 6, 9, up to 100 days of follow up</time_frame>
    <description>28 days/cycle for combination therapy of Urelumab and Nivolumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(INF) of urelumab and nivolumab when co-administered</measure>
    <time_frame>Cycle 1, 2, 3, 4, 5, 6, 9, up to 100 days of follow up</time_frame>
    <description>28 days/cycle for combination therapy of Urelumab and Nivolumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T-HALF of urelumab when co-administered</measure>
    <time_frame>Cycle 1, 2, 3, 4, 5, 6, 9, up to 100 days of follow up</time_frame>
    <description>28 days/cycle for combination therapy of Urelumab and Nivolumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLT of urelumab when co-administered</measure>
    <time_frame>Cycle 1, 2, 3, 4, 5, 6, 9, up to 100 days of follow up</time_frame>
    <description>28 days/cycle for combination therapy of Urelumab and Nivolumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vss of urelumab when co-administered</measure>
    <time_frame>Cycle 1, 2, 3, 4, 5, 6, 9, up to 100 days of follow up</time_frame>
    <description>28 days/cycle for combination therapy of Urelumab and Nivolumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-drug Antibody (ADA) status of the subject in response to Urelumab when administered alone</measure>
    <time_frame>Cycle 1, 2, 4, 8, 12, 16, up to 60 days of follow up</time_frame>
    <description>21 days/cycle for Urelumab monotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADA status of the subject in response to Urelumab and Nivolumab when co-administered</measure>
    <time_frame>Cycle 1, 2, 4, 5, 9, up to 100 days of follow up</time_frame>
    <description>28 days/cycle for combination therapy of Urelumab and Nivolumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response (BOR) of urelumab monotherapy</measure>
    <time_frame>Every 6-8 weeks during the treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BOR of urelumab and nivolumab combination therapy</measure>
    <time_frame>Every 6-8 weeks during the treatment period</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Malignant Tumors</condition>
  <arm_group>
    <arm_group_label>Urelumab (+ Nivolumab) intravenous (IV) infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Urelumab</intervention_name>
    <arm_group_label>Urelumab (+ Nivolumab) intravenous (IV) infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <arm_group_label>Urelumab (+ Nivolumab) intravenous (IV) infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Subjects with previously treated advanced malignant solid tumor

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1

          -  For certain subjects, willing and able to provide pre-treatment tumor sample

        Exclusion Criteria:

          -  Known or suspected central nervous system metastases or central nervous system as the
             only source of disease

          -  Other concomitant malignancies (with some exceptions per protocol)

          -  Active, known or suspected autoimmune disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kobe-shi</city>
        <state>Hyogo</state>
        <zip>6500017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>August 5, 2015</study_first_submitted>
  <study_first_submitted_qc>August 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2015</study_first_posted>
  <last_update_submitted>May 14, 2020</last_update_submitted>
  <last_update_submitted_qc>May 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced malignant tumors</keyword>
  <keyword>Metastatic malignant tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

